Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganluotong Chewable Tablets in Portal Hypertension Due to HBV Cirrhosis
CTR20140184Phase 2Active
- Sponsor
- Sichuan Yatai Pharmaceutical
- Start
- Feb 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Ganluotong in Portal Hypertension (PH), Cirrhosis, Chronic Hepatitis B (CHB), sponsored by Sichuan Yatai Pharmaceutical. Started Feb 2014; status: active.
02
Drugs
Ganluotong
03
Conditions
Portal Hypertension (PH)CirrhosisChronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20140184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140184.